Bellicum Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the United States and internationally. The company's clinical product candidates include BPX-501, an adjunct T cell therapy in multiple Phase I/II clinical trials, administered after allogeneic hematopoietic stem cell transplantation; and BPX-601, a GoCAR-T product candidate in Phase I clinical trial for treating solid tumors expressing the prostate stem cell antigen. Its clinical product candidates also comprise BPX-701, a T cell receptors (TCR) based therapy in Phase I clinical trial for the treatment of malignant cells expressing the preferentially-expressed antigen in melanoma; and CD19, a chimeric antigen receptor T cell therapy for expressing B cell malignancies setting. It has collaboration agreements with Adaptimmune Therapeutics plc to evaluate, develop, and commercialize T cell therapies; and Academisch Ziekenhuis Leiden for research to discover and validate high-affinity TCR product candidates targeting various cancer-associated antigens. Bellicum Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Houston, Texas.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:BLCM
CUSIPN/A
Phone832-384-1100
Debt
Debt-to-Equity Ratio0.32
Current Ratio10.24
Quick Ratio10.24
Price-To-Earnings
Trailing P/E Ratio-2.19
Forward P/E Ratio-2.66
P/E GrowthN/A
Sales & Book Value
Annual Sales$190,000.00
Price / Sales1,419.14
Cash FlowN/A
Price / CashN/A
Book Value$2.55 per share
Price / Book2.44
Profitability
EPS (Most Recent Fiscal Year)($2.84)
Net Income$-91,770,000.00
Net MarginsN/A
Return on Equity-98.87%
Return on Assets-64.46%
Miscellaneous
Employees137
Outstanding Shares43,350,000
Market Cap$269.63 million
Bellicum Pharmaceuticals (NASDAQ:BLCM) Frequently Asked Questions
What is Bellicum Pharmaceuticals' stock symbol?
Bellicum Pharmaceuticals trades on the NASDAQ under the ticker symbol "BLCM."
How were Bellicum Pharmaceuticals' earnings last quarter?
Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) released its quarterly earnings data on Tuesday, August, 7th. The biopharmaceutical company reported ($0.60) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.55) by $0.05. The biopharmaceutical company had revenue of $0.36 million for the quarter, compared to analysts' expectations of $0.08 million. View Bellicum Pharmaceuticals' Earnings History.
When is Bellicum Pharmaceuticals' next earnings date?
What price target have analysts set for BLCM?
6 analysts have issued 12-month price targets for Bellicum Pharmaceuticals' shares. Their forecasts range from $6.85 to $19.00. On average, they anticipate Bellicum Pharmaceuticals' stock price to reach $15.57 in the next twelve months. This suggests a possible upside of 150.3% from the stock's current price. View Analyst Price Targets for Bellicum Pharmaceuticals.
What is the consensus analysts' recommendation for Bellicum Pharmaceuticals?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bellicum Pharmaceuticals in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Bellicum Pharmaceuticals.
What are Wall Street analysts saying about Bellicum Pharmaceuticals stock?
Here are some recent quotes from research analysts about Bellicum Pharmaceuticals stock:
- 1. Cantor Fitzgerald analysts commented, "Complex Cases. The three cases of encephalopathy occurred in three patients, certain of whom had failed prior transplantation, have a history of immunodeficiency, infection, and/or treatment with rimiducid and other medications. To-date, Bellicum has treated over 240 patients with allogeneic haploidentical transplants with limited rates of transplant-related mortality. This compares to historical studies of allogeneic transplantation by the Center for International Blood & Marrow Transplant Research that have demonstrated that more than a third of deaths occur from occurrences of GvHD and infection, which BPX-501 is aimed at addressing. That being said, we are not yet clear on the relationship of these encephalopathy events to BPX-501 treatment, which lowers our overall confidence in the BPX-501 program." (1/31/2018)
- 2. According to Zacks Investment Research, "Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It is focused on discovering and developing cellular immunotherapies for various forms of cancer, including both hematological and solid tumors, as well as orphan inherited blood disorders. The Company's lead clinical product candidate is BPX-501, an adjunct T-cell therapy in multiple Phase I/II clinical trials. It is also developing BPX-201, a dendritic cell cancer vaccine, which is in a Phase I clinical trial for the treatment of metastatic castrate-resistant prostate cancer. Bellicum Pharmaceuticals, Inc. is based in Houston, Texas. " (1/22/2018)
Who are some of Bellicum Pharmaceuticals' key competitors?
Some companies that are related to Bellicum Pharmaceuticals include Retrophin (RTRX), Apellis Pharmaceuticals (APLS), Radius Health (RDUS), Assembly Biosciences (ASMB), TG Therapeutics Inc common stock (TGTX), Revance Therapeutics (RVNC), Tricida (TCDA), MacroGenics (MGNX), AMAG Pharmaceuticals (AMAG), Flexion Therapeutics (FLXN), Rocket Pharmaceuticals (RCKT), Omeros (OMER), Amarin (AMRN), Dynavax Technologies (DVAX) and Amphastar Pharmaceuticals (AMPH).
Who are Bellicum Pharmaceuticals' key executives?
Bellicum Pharmaceuticals' management team includes the folowing people:
- Mr. Richard A. Fair, Pres, CEO & Director (Age 49)
- Mr. Alan A. Musso CPA, C.M.A., CFO & Treasurer (Age 56)
- Dr. Alan K. Smith, Exec. VP of Technical Operations (Age 60)
- Mr. Thomas J. Farrell, Consultant (Age 55)
- Dr. Annemarie Moseley, Former Chief Operating Officer and Exec. VP of Clinical Devel. (Age 63)
When did Bellicum Pharmaceuticals IPO?
(BLCM) raised $101 million in an initial public offering (IPO) on Thursday, December 18th 2014. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Jefferies, Citigroup and Piper Jaffray served as the underwriters for the IPO and Trout Capital was co-manager.
Has Bellicum Pharmaceuticals been receiving favorable news coverage?
Media headlines about BLCM stock have trended somewhat positive on Wednesday, Accern Sentiment Analysis reports. The research group ranks the sentiment of news coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Bellicum Pharmaceuticals earned a daily sentiment score of 0.20 on Accern's scale. They also gave media coverage about the biopharmaceutical company an impact score of 46.22 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near term. View Recent Headlines for Bellicum Pharmaceuticals.
Who are Bellicum Pharmaceuticals' major shareholders?
Bellicum Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Baker BROS. Advisors LP (9.44%), BlackRock Inc. (7.26%), FMR LLC (4.32%), Frazier Management LLC (2.43%), Wasatch Advisors Inc. (2.15%) and Millennium Management LLC (1.69%). Company insiders that own Bellicum Pharmaceuticals stock include Alan A Musso, Alan K Smith, Annemarie Moseley, Bros Advisors Lp Baker, David M Spencer, Ken Moseley and Kevin M Slawin. View Institutional Ownership Trends for Bellicum Pharmaceuticals.
Which institutional investors are selling Bellicum Pharmaceuticals stock?
BLCM stock was sold by a variety of institutional investors in the last quarter, including FMR LLC and Baker BROS. Advisors LP. Company insiders that have sold Bellicum Pharmaceuticals company stock in the last year include Alan A Musso, Alan K Smith, Bros Advisors Lp Baker and David M Spencer. View Insider Buying and Selling for Bellicum Pharmaceuticals.
Which institutional investors are buying Bellicum Pharmaceuticals stock?
BLCM stock was acquired by a variety of institutional investors in the last quarter, including Frazier Management LLC, BlackRock Inc., Wasatch Advisors Inc., Millennium Management LLC, ARK Investment Management LLC, RTW Investments LP, Rhumbline Advisers and Schwab Charles Investment Management Inc.. View Insider Buying and Selling for Bellicum Pharmaceuticals.
How do I buy shares of Bellicum Pharmaceuticals?
Shares of BLCM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Bellicum Pharmaceuticals' stock price today?
One share of BLCM stock can currently be purchased for approximately $6.22.
How big of a company is Bellicum Pharmaceuticals?
Bellicum Pharmaceuticals has a market capitalization of $269.63 million and generates $190,000.00 in revenue each year. The biopharmaceutical company earns $-91,770,000.00 in net income (profit) each year or ($2.84) on an earnings per share basis. Bellicum Pharmaceuticals employs 137 workers across the globe.
How can I contact Bellicum Pharmaceuticals?
Bellicum Pharmaceuticals' mailing address is 2130 WEST HOLCOMBE BOULEVARD SUITE 800, HOUSTON TX, 77030. The biopharmaceutical company can be reached via phone at 832-384-1100 or via email at [email protected]
MarketBeat Community Rating for Bellicum Pharmaceuticals (NASDAQ BLCM)
MarketBeat's community ratings are surveys of what our community members think about Bellicum Pharmaceuticals and other stocks. Vote "Outperform" if you believe BLCM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BLCM will underperform the S&P 500 over the long term. You may vote once every thirty days.
